X-Therma lands a cool $22.4m to advance cryopreservation platform

Cryotechnology company targets regenerative medicine and organ transplantation with a range of preservation and transportation solutions.

Cryopreservation technology company X-Therma has concluded an oversubscribed Series B funding round, securing $22.4 million to advance its platform for regenerative medicine and organ preservation. The company is aiming to transform cold chain technology, improving global access to organs, engineered tissues, and regenerative therapies.

The range of products in X-Therma’s pipeline are designed to tackle specific challenges in regenerative medicine and organ transplantation. From non-toxic cryopreservation solutions for regenerative medicines and organs to transport solutions specifically designed for organs and biologics, the company is developing a range of alternatives to traditional cryopreservation approaches.

By extending organ preservation times and addressing critical time-sensitive limitations in the process, X-Therma aims to increase organ availability for transplantation with technologies designed to ensure high cell recovery and functionality.

Dr Xiaoxi Wei, co-founder and CEO of X-Therma, said that the company’s products “could eliminate time as a critical constraint, with the potential to save millions of lives.”

X-Therma lands a cool $22.4m to advance cryopreservation platform
Dr Xiaoxi Wei, X-Therma co-founder and CEO

Based in the San Francisco Bay Area, with operations in Austria, X-Therma says it plans to use the new funding to gear up for clinical trials and global expansion.

“This funding marks a pivotal moment as we prepare to launch our GMP-grade cryopreservation and cold-chain solutions into the commercial market, responding to growing demand in cell and gene therapy and bioprocessing,” said Wei. “We are ready to get our products to customers and patients and begin getting more organs to patients around the globe. You have time.”

The new funding round was co-led by new investor Starling Locke Capital and existing investor LOREA AG.

“Despite the capital winter challenging the life sciences sector, X-Therma stands out with its exceptional resilience and potential,” said Johannes Weggemann, Managing Director at LOREA AG.

Photographs courtesy of X-Therma